Among them, 57 interferon genes responsible for activating a type-1 interferon response mediated by interferon alpha1 (IFNA1), interferon beta1 (IFNB1) and Chemokine (C-X-C motif) ligand 9 (CXCL9, a ligand acting on the receptor CXCR3 on T cells to attract them into the tumor bed) upregulation in in vitro MM cells, correlating with the clinical outcome of MM patients treated with BTZ-based regimens (Galluzzi et al., 2020[44]). This evidence concerns the gene IFNA1 and Miyoshi myopathy.